AEON Biopharma, Inc. (AEON) Research

AEON Biopharma, Inc. is a biopharmaceutical company primarily engaged in developing therapies based on botulinum toxins, aimed at treating various debilitating medical conditions. Among its key investigational products is ABP-450, a 900 kDa botulinum toxin complex, which is being advanced for therapeutic use in conditions such as migraine, cervical dystonia, and gastroparesis. The entity, originally known as ALPHAEON Corporation, adopted the name AEON Biopharma, Inc. in December 2019. Established in 2012, the company maintains its principal operations from Newport Beach, California.

Market snapshot

Symbol
AEON
Price
$0.67
Day change
-0.83%
Market cap
$7.9M
P/E ratio
-0.13x
52-week range
0.51-1.45
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months

Peer companies

  • Abpro Corporation (ABP)
  • Aptorum Group Limited (APM)
  • Bolt Biotherapeutics, Inc. (BOLT)
  • Cingulate Inc. (CING)
  • Clene Inc. (CLNN)
  • Cellectar Biosciences, Inc. (CLRB)
  • Lyra Therapeutics, Inc. (LYRA)
  • Mustang Bio, Inc. (MBIO)

Recent insider activity

  • Bencich John — A-Award (754717 shares) on 2026-04-02
  • Bencich John — trade (0 shares) on 2026-04-01
  • Oh Chad — A-Award (1316872 shares) on 2026-03-04
  • Oh Chad — A-Award (862500 shares) on 2026-02-17
  • Wilson Alexander Blair — A-Award (1316872 shares) on 2026-03-04

Open AEON Biopharma, Inc. (AEON) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.